69 related articles for article (PubMed ID: 20043096)
1. Pancreatic cancer therapy with a novel pump for controlled drug release.
Haramoto M; Kohno M; Nakajima O; Horibe T; Kiyohara M; Fukazawa H; Togawa T; Kawakami K
Oncol Rep; 2010 Feb; 23(2):365-70. PubMed ID: 20043096
[TBL] [Abstract][Full Text] [Related]
2. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
3. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
5. Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts.
Smith JP; Kanekal S; Patawaran MB; Chen JY; Jones RE; Orenberg EK; Yu NY
Cancer Chemother Pharmacol; 1999; 44(4):267-74. PubMed ID: 10447573
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
[TBL] [Abstract][Full Text] [Related]
7. [Comparison between intraperitoneal and intravenous 5-fluorouracil administration using pancreatic cancer model of nude mouse].
Maruyama M; Yuasa Y; Endo M
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1785-8. PubMed ID: 9382533
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
9. Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.
You MH; Kim WJ; Shim W; Lee SR; Lee G; Choi S; Kim DY; Kim YM; Kim H; Han SU
J Gastroenterol Hepatol; 2009 Aug; 24(8):1393-400. PubMed ID: 19486256
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.
Lutz MP; Königer M; Muche R; Ellenrieder V; Steinkamp M; Adler G; Gress TM
Z Gastroenterol; 1999 Oct; 37(10):993-7. PubMed ID: 10549093
[TBL] [Abstract][Full Text] [Related]
11. Microprocessor-controlled iontophoretic drug delivery of 5-fluorouracil: pharmacodynamic and pharmacokinetic study.
Chandrashekar NS; Shobha Rani RH
J BUON; 2007; 12(4):529-34. PubMed ID: 18067212
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
13. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
Oman M; Lundqvist S; Gustavsson B; Hafström LO; Naredi P
Cancer Chemother Pharmacol; 2005 Dec; 56(6):603-9. PubMed ID: 16047145
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
[TBL] [Abstract][Full Text] [Related]
17. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.
Kisker O; Becker CM; Prox D; Fannon M; D'Amato R; Flynn E; Fogler WE; Sim BK; Allred EN; Pirie-Shepherd SR; Folkman J
Cancer Res; 2001 Oct; 61(20):7669-74. PubMed ID: 11606410
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
[TBL] [Abstract][Full Text] [Related]
19. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
20. Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV.
Oman M; Blind PJ; Naredi P; Gustavsson B; Hafström LO
Eur J Surg Oncol; 2001 Aug; 27(5):477-81. PubMed ID: 11504519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
